Search research articles
Contact Us
Filters
Showing results (151-160 of 204) with videos related to
Page
of 21
Sort By:
Plos One
|
November 16, 2016
MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study
Okyaz Eminaga, Wei Wei, Sarah J Hawley, et al.
Cancer Research
|
July 27, 2021
RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer
Mark P Labrecque, Lisha G Brown, Ilsa M Coleman, et al.
Cell
|
May 10, 2024
Analysis of 3D pathology samples using weakly supervised AI
Andrew H Song, Mane Williams, Drew F K Williamson, et al.
Cancer Research Communications
|
November 7, 2022
Comprehensive assessment of anaplastic lymphoma kinase in localized and metastatic prostate cancer reveals targetable alterations
Radhika A Patel, Ilsa Coleman, Martine P Roudier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 9, 2017
Association of Tissue Abiraterone Levels and <i>SLCO</i> Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer
Elahe A Mostaghel, Eunpi Cho, Ailin Zhang, et al.
Cancer Research Communications
|
October 12, 2023
Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
Ailin Zhang, Nathan A Lau, Alicia Wong, et al.
The Journal of Clinical Investigation
|
October 19, 2018
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
Adam Sharp, Ilsa Coleman, Wei Yuan, et al.
JCO Precision Oncology
|
May 25, 2019
Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations
Michael T Schweizer, Emmanuel S Antonarakis, Tarek A Bismar, et al.
The Journal of Clinical Investigation
|
September 19, 2023
Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models
Supreet Agarwal, Lei Fang, Kerry McGowen, et al.
The Prostate
|
March 23, 2021
Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer
Laura S Graham, Lawrence D True, Roman Gulati, et al.
Page
of 21
Search research articles
Search
Showing results (151-160 of 204) with videos related to
Sort By:
Page
of 21
Plos One
|
November 16, 2016
MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study
Okyaz Eminaga, Wei Wei, Sarah J Hawley, et al.
Cancer Research
|
July 27, 2021
RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer
Mark P Labrecque, Lisha G Brown, Ilsa M Coleman, et al.
Cell
|
May 10, 2024
Analysis of 3D pathology samples using weakly supervised AI
Andrew H Song, Mane Williams, Drew F K Williamson, et al.
Cancer Research Communications
|
November 7, 2022
Comprehensive assessment of anaplastic lymphoma kinase in localized and metastatic prostate cancer reveals targetable alterations
Radhika A Patel, Ilsa Coleman, Martine P Roudier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 9, 2017
Association of Tissue Abiraterone Levels and <i>SLCO</i> Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer
Elahe A Mostaghel, Eunpi Cho, Ailin Zhang, et al.
Cancer Research Communications
|
October 12, 2023
Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
Ailin Zhang, Nathan A Lau, Alicia Wong, et al.
The Journal of Clinical Investigation
|
October 19, 2018
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
Adam Sharp, Ilsa Coleman, Wei Yuan, et al.
JCO Precision Oncology
|
May 25, 2019
Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations
Michael T Schweizer, Emmanuel S Antonarakis, Tarek A Bismar, et al.
The Journal of Clinical Investigation
|
September 19, 2023
Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models
Supreet Agarwal, Lei Fang, Kerry McGowen, et al.
The Prostate
|
March 23, 2021
Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer
Laura S Graham, Lawrence D True, Roman Gulati, et al.
Page
of 21